ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ACTR-50. MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY
Neuro-Oncology
◽
10.1093/neuonc/now212.048
◽
2016
◽
Vol 18
(suppl_6)
◽
pp. vi13-vi13
Author(s):
Daniela Bota
◽
Annick Desjardins
◽
Warren Mason
◽
Howard Fine
◽
Santosh Kesari
◽
...
Keyword(s):
Malignant Glioma
◽
Phase 1
◽
Open Label
◽
Who Grade
◽
Open Label Study
◽
Label Study
Download Full-text
Related Documents
Cited By
References
ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS
Neuro-Oncology
◽
10.1093/neuonc/noy148.073
◽
2018
◽
Vol 20
(suppl_6)
◽
pp. vi20-vi20
Author(s):
Daniela A Bota
◽
Santosh Kesari
◽
David Piccioni
◽
Dawit Aregawi
◽
Patrick Roth
◽
...
Keyword(s):
Malignant Glioma
◽
Phase 1
◽
Newly Diagnosed
◽
Open Label
◽
Who Grade
◽
Open Label Study
◽
Label Study
Download Full-text
A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results.
Journal of Clinical Oncology
◽
10.1200/jco.2018.36.15_suppl.e14083
◽
2018
◽
Vol 36
(15_suppl)
◽
pp. e14083-e14083
◽
Cited By ~ 1
Author(s):
Daniela Annenelie Bota
◽
Santosh Kesari
◽
David Eric Piccioni
◽
Dawit Gebremichael Aregawi
◽
Patrick Roth
◽
...
Keyword(s):
Malignant Glioma
◽
Dose Escalation
◽
Phase 1
◽
Newly Diagnosed
◽
Open Label
◽
Who Grade
◽
Open Label Study
◽
Label Study
Download Full-text
ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM)
Neuro-Oncology
◽
10.1093/neuonc/nox168.058
◽
2017
◽
Vol 19
(suppl_6)
◽
pp. vi16-vi16
◽
Cited By ~ 1
Author(s):
Daniela Bota
◽
Annick Desjardins
◽
Warren Mason
◽
Santosh Kesari
◽
Rajiv Magge
◽
...
Keyword(s):
Malignant Glioma
◽
Phase 1
◽
Open Label
◽
Who Grade
◽
Open Label Study
◽
Label Study
Download Full-text
ACTR-45. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM)
Neuro-Oncology
◽
10.1093/neuonc/nox168.036
◽
2017
◽
Vol 19
(suppl_6)
◽
pp. vi10-vi10
Author(s):
Daniela Bota
◽
Warren Mason
◽
Santosh Kesari
◽
David Piccioni
◽
Dawit Aregawi
◽
...
Keyword(s):
Malignant Glioma
◽
Phase 1
◽
Newly Diagnosed
◽
Open Label
◽
Who Grade
◽
Open Label Study
◽
Label Study
Download Full-text
Phase 1 First Time in Humans (FTIH), Open Label Study of GSK3745417 Administered to Subjects With Advanced Solid Tumors
Case Medical Research
◽
10.31525/ct1-nct03843359
◽
2000
◽
Author(s):
Keyword(s):
Solid Tumors
◽
Phase 1
◽
Advanced Solid Tumors
◽
Open Label
◽
Open Label Study
◽
Label Study
◽
First Time
Download Full-text
Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of dilpacimab in patients with advanced solid tumors
Molecular Cancer Therapeutics
◽
10.1158/1535-7163.mct-20-0985
◽
2021
◽
pp. molcanther.0985.2020
Author(s):
Michael S. Gordon
◽
John Nemunaitis
◽
Minal Barve
◽
Zev A. Wainberg
◽
Erika P. Hamilton
◽
...
Keyword(s):
Solid Tumors
◽
Phase 1
◽
Advanced Solid Tumors
◽
Open Label
◽
Open Label Study
◽
Label Study
Download Full-text
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Journal of Hematology & Oncology
◽
10.1186/s13045-018-0681-6
◽
2018
◽
Vol 11
(1)
◽
Cited By ~ 125
Author(s):
Wan-Hong Zhao
◽
Jie Liu
◽
Bai-Yan Wang
◽
Yin-Xia Chen
◽
Xing-Mei Cao
◽
...
Keyword(s):
Multiple Myeloma
◽
Cell Therapy
◽
Phase 1
◽
Cell Maturation
◽
Open Label
◽
T Cell Therapy
◽
Open Label Study
◽
Label Study
◽
B Cell Maturation
◽
B Cell Maturation Antigen
Download Full-text
Single‐ and multiple‐dose pharmacokinetics and safety of pimodivir, a novel, non‐nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open‐label study in healthy volunteers
British Journal of Clinical Pharmacology
◽
10.1111/bcp.13733
◽
2018
◽
Vol 84
(11)
◽
pp. 2663-2672
◽
Cited By ~ 6
Author(s):
Sofie Deleu
◽
Thomas N. Kakuda
◽
Kurt Spittaels
◽
Jurgen J. Vercauteren
◽
Vera Hillewaert
◽
...
Keyword(s):
Healthy Volunteers
◽
Influenza A Virus
◽
Influenza A
◽
Multiple Dose
◽
Basic Protein
◽
Phase 1
◽
Open Label
◽
Open Label Study
◽
Label Study
◽
Multiple Dose Pharmacokinetics
Download Full-text
Abstract C37: A Phase 1 open‐label study evaluating pharmacokinetics, safety, and tolerability of linifanib in Japanese patients with solid tumors
10.1158/1535-7163.targ-09-c37
◽
2009
◽
Author(s):
Tomohide Tamura
◽
Noboru Yamamoto
◽
Hiroshi Nokihara
◽
Yasuhide Yamada
◽
Hajime Asahina
◽
...
Keyword(s):
Solid Tumors
◽
Phase 1
◽
Japanese Patients
◽
Open Label
◽
Open Label Study
◽
Label Study
Download Full-text
A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.
Journal of Clinical Oncology
◽
10.1200/jco.2015.33.15_suppl.tps5072
◽
2015
◽
Vol 33
(15_suppl)
◽
pp. TPS5072-TPS5072
◽
Cited By ~ 14
Author(s):
Robert B. Montgomery
◽
Emmanuel S. Antonarakis
◽
Maha Hussain
◽
Karim Fizazi
◽
Anthony M. Joshua
◽
...
Keyword(s):
Prostate Cancer
◽
Antitumor Activity
◽
Phase 1
◽
Castration Resistant Prostate Cancer
◽
Open Label
◽
Open Label Study
◽
Label Study
◽
Terminal Domain
◽
Castration Resistant
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close